全文获取类型
收费全文 | 6818篇 |
免费 | 272篇 |
国内免费 | 43篇 |
专业分类
耳鼻咽喉 | 94篇 |
儿科学 | 311篇 |
妇产科学 | 70篇 |
基础医学 | 978篇 |
口腔科学 | 71篇 |
临床医学 | 453篇 |
内科学 | 1535篇 |
皮肤病学 | 124篇 |
神经病学 | 558篇 |
特种医学 | 228篇 |
外科学 | 1023篇 |
综合类 | 18篇 |
一般理论 | 1篇 |
预防医学 | 165篇 |
眼科学 | 108篇 |
药学 | 524篇 |
中国医学 | 23篇 |
肿瘤学 | 849篇 |
出版年
2023年 | 36篇 |
2022年 | 83篇 |
2021年 | 134篇 |
2020年 | 102篇 |
2019年 | 105篇 |
2018年 | 137篇 |
2017年 | 134篇 |
2016年 | 138篇 |
2015年 | 136篇 |
2014年 | 195篇 |
2013年 | 226篇 |
2012年 | 379篇 |
2011年 | 485篇 |
2010年 | 295篇 |
2009年 | 269篇 |
2008年 | 418篇 |
2007年 | 427篇 |
2006年 | 444篇 |
2005年 | 495篇 |
2004年 | 489篇 |
2003年 | 478篇 |
2002年 | 399篇 |
2001年 | 53篇 |
2000年 | 47篇 |
1999年 | 64篇 |
1998年 | 107篇 |
1997年 | 87篇 |
1996年 | 77篇 |
1995年 | 79篇 |
1994年 | 67篇 |
1993年 | 74篇 |
1992年 | 41篇 |
1991年 | 33篇 |
1990年 | 35篇 |
1989年 | 50篇 |
1988年 | 51篇 |
1987年 | 22篇 |
1986年 | 27篇 |
1985年 | 28篇 |
1984年 | 35篇 |
1983年 | 18篇 |
1982年 | 28篇 |
1981年 | 16篇 |
1980年 | 10篇 |
1979年 | 11篇 |
1978年 | 20篇 |
1977年 | 9篇 |
1976年 | 10篇 |
1975年 | 6篇 |
1970年 | 6篇 |
排序方式: 共有7133条查询结果,搜索用时 0 毫秒
91.
92.
Guidelines for treatment of ulcerative colitis in children 总被引:2,自引:0,他引:2
Takeshi Tomomasa Akio Kobayashi Kousuke Ushijima Keiichi Uchida Seiichi Kagimoto Toshiaki Shimizu Hitoshi Tajiri Takuhiro Tahara Atushi Yoden for the Working Group of the Japanese Society for Pediatric Gastroenterology Hepatology Nutrition 《Pediatrics international》2004,46(4):494-496
This paper introduces the guidelines for treatment of ulcerative colitis in children, created by the working group of the Japanese Society for Pediatric Gastroenterology, Hepatology and Nutrition (Chair: Yuichiro Yamashiro) and the Japanese Society for Pediatric Inflammatory Bowel Disease (IBD) (Chair: Akio Kobayashi). The ideas of the working group, with regard to the fundamental differences in medical treatment between children and adults, included: (1) for children, intensive medical treatment including appropriate systemic management is important during the acute phase of illness. (2) Treatment with steroids, which can cause growth disturbances, should not be continued for long periods of time. (3) Pulsed steroid therapy, selective removal of blood cells, and intravenous infusion of cyclosporin should be included in the therapeutic option for severe and fluminant cases. 相似文献
93.
Wang L Kuroiwa Y Kamitani T Li M Takahashi T Suzuki Y Shimamura M Hasegawa O 《Journal of neurology》2000,247(5):356-363
To determine whether there are characteristic changes in event-related potentials (ERPs) in parkinsonian syndromes we studied
8 patients with progressive supranuclear palsy (PSP), 10 patients with corticobasal degeneration (CBD), 9 patients with striatonigral
degeneration (SND), and 16 patients with idiopathic Parkinson's disease (PD) with a mean duration of illness shorter than
5 years in each group. A visual oddball paradigm was employed to elicit P300. P300 to the rare target and rare nontarget stimuli
and reaction time (RT) to rare target stimuli in each group were compared with those in the corresponding age-matched normal
control group and to each other after age correction. The correlation of P300 and RT to motor disability score was also studied.
In PSP P300 amplitude was markedly reduced while in CBD P300 latency was prolonged. P300 amplitude to rare nontargets in SND
and PD was attenuated. The mean RT in the PSP and the CBD group was significantly longer than in the other two groups. The
mean RT in PD and P300 amplitude to rare nontargets in both CBD and PD showed significant correlation with the severity of
motor disability. Simultaneous measurement of P300 and RT may yield useful supplementary information in facilitating diagnosis
of parkinsonian syndromes in addition to clinical criteria.
Received: 6 April 1999, Received in revised form: 5 August 1999, Accepted: 12 January 2000 相似文献
94.
No Improvement of Adult Height in Non-growth Hormone (GH) Deficient Short
Children with GH Treatment
Toshiaki Tanaka Kenji Fujieda Susumu Yokoya Akira Shimatsu Katsuhiko Tachibana Hiroyuki Tanaka Takakuni Tanizawa Akira Teramoto Toshiro Nagai Yoshikazu Nishi Yukihiro Hasegawa Kunihiko Hanew Keinosuke Fujita Reiko Horikawa Goro Takada Masao Miyashita Tadashi Ohno Kazuo Komatsu 《Clinical Pediatric Endocrinology》2006,15(1):15-21
It is still in doubt whether the standard-dose growth hormone (GH) used in Japan (0.5
IU/kg/week, 0.167 mg/kg/week) for growth hormone deficiency is effective for achieving
significant adult height improvement in non-growth hormone deficient (non-GHD) short
children. We compared the growth of GH-treated non-GHD short children with that of
untreated short children to examine the effect of standard-dose GH treatment on non-GHD
short children. GH treatment with recombinant human growth hormone (rhGH) was started
before the age of 11 yr in 64 boys and 76 girls with non-GHD short stature registered at
the Foundation for Growth Science who have now reached their adult height. In 119
untreated boys and 127 untreated girls whose height standard deviation score (SDS) was
below –2 SD at the age of 6 yr, height growth was followed until 17 yr. Height SDS was
significantly lower before GH treatment in the GH-treated group than at the age of 6 yr in
the untreated group, in both sexes. Adult height and adult height SDS were significantly
greater in the untreated group than in the GH-treated group, in both sexes, although the
change in height SDS did not differ significantly. Height SDS was significantly lower
before GH treatment in the GH-treated group than at the age of 6 yr in the untreated
group, so 57 boys and 57 girls whose height SDS at the age of 6 yr in the untreated group
closely matched the height SDS before GH treatment in the GH-treated group were chosen for
comparison. Height SDS did not differ significantly between the GH-treated group before GH
treatment and the untreated group at the age of 6 yr, nor were there differences between
these subgroups in adult height, adult height SDS, or height SDS change, in either sex.
The effect of GH treatment is reported to be dose-dependent and doses over 0.23 mg/kg/week
are reported to be necessary to improve adult height in non-GHD short children. Currently,
the GH dose is fixed at 0.175 mg/kg/week in Japan, and we expected to find, and indeed
concluded, that ordinary GH treatment in Japanese, non-GHD short children does not improve
adult height. 相似文献
95.
Takuji Suzuki Tatsuro Fukuhara Masashi Tanaka Akira Nakamura Kenichi Akiyama Tomohiro Sakakibara Daizo Koinuma Toshiaki Kikuchi Ryushi Tazawa Makoto Maemondo Koichi Hagiwara Yasuo Saijo Toshihiro Nukiwa 《Clinical cancer research》2005,11(1):58-66
Cancer immunotherapy by fusion of antigen-presenting cells and tumor cells has been shown to induce potent antitumor immunity. In this study, we characterized syngeneic and allogeneic, murine macrophage/dendritic cell (DC)-cancer fusion cells for the antitumor effects. The results showed the superiority of allogeneic cells as fusion partners in both types of antigen-presenting cells in an in vivo immunotherapy model. A potent induction of tumor-specific CTLs was observed in these immunized conditions. In addition, the immunization with DC-cancer fusion cells was better than that with macrophage-cancer fusion cells. Both syngeneic and allogeneic DC-cancer fusion cells induced higher levels of IFN-gamma production than macrophage-cancer fusion cells. Interestingly, allogeneic DC-cancer fusion cells were superior in that they efficiently induced Th1-type cytokines but not the Th2-type cytokines interleukin (IL)-10 and IL-4, whereas syngeneic DC-cancer fusion cells were powerful inducers of both Th1 and Th2 cytokines. These results suggest that allogeneic DCs are suitable as fusion cells in cancer immunotherapy. To further enhance the antitumor immunity in the clinical setting, we prepared DCs fused with IL-12 gene-transferred cancer cells and thus generated IL-12-secreting DC-cancer fusion cells. Immunization with these gene-modified DC-cancer fusion cells was able to elicit a markedly enhanced antitumor effect in the in vivo therapeutic model. This novel IL-12-producing fusion cell vaccine might be one promising intervention for future cancer immunotherapy. 相似文献
96.
97.
Carbonic anhydrase II is a tumor vessel endothelium-associated antigen targeted by dendritic cell therapy. 总被引:3,自引:0,他引:3
Kenta Yoshiura Takashi Nakaoka Toshihide Nishishita Katsuaki Sato Akifumi Yamamoto Shinji Shimada Toshiaki Saida Yutaka Kawakami Tsuneo A Takahashi Hiroyuki Fukuda Shinobu Imajoh-Ohmi Naoki Oyaizu Naohide Yamashita 《Clinical cancer research》2005,11(22):8201-8207
Tumor-associated antigens are promising candidates as target molecules for immunotherapy and a wide variety of tumor-associated antigens have been discovered through the presence of serum antibodies in cancer patients. We previously conducted dendritic cell therapy on 10 malignant melanoma patients and shrinkage or disappearance of metastatic tumors with massive necrosis occurred in two patients. In this study, we found a 29-kDa protein against which antibody was elicited by dendritic cell therapy in one of the two patients. Matrix-assisted laser desorption ionization-time of flight/mass spectrometry analysis of the protein isolated by two-dimensional electrophoresis combined with Western blots revealed that the 29-kDa protein was carbonic anhydrase II (CA-II). Immunohistochemistry of the tumors and normal tissues showed that CA-II was expressed in the tumor vessel but not in normal vessel endothelium. CA-II expression in tumor endothelium was observed as well in other cancers including esophageal, renal, and lung cancers. In an in vitro angiogenesis model, CA-II expression of normal human vein endothelial cells was significantly up-regulated when cells were cultured in the acidic and hypoxic conditions indicative of a tumor environment. These findings suggest that CA-II is a tumor vessel endothelium-associated antigen in melanoma and other cancers, and elicitation of serum anti-CA-II antibody by dendritic cell therapy may be associated with good clinical outcome including tumor reduction. 相似文献
98.
Toshiaki Watanabe Takamitsu Kanazawa Yoshihiro Kazama Junichiro Tanaka Toshiaki Tanaka Soichiro Ishihara Hirokazu Nagawa 《Journal of clinical oncology》2005,23(35):9031-2; author reply 9032-3
99.
Toshiaki Tanaka Agnès Duflot-Dancer Michèle Tiraby Colette Piccoli Gérard Tiraby Hiroshi Yamasaki Marc Mesnil 《Cancer letters》2009
Among gene therapy strategies elaborated to kill cancer cells, one uses the CodA gene, coding for cytosine deaminase (CD) that converts 5-fluorocytosine (5-FC) into toxic 5-fluorouracil (5-FU). To enhance 5-FC metabolic activation, we prepared a vector carrying CodA and upp (uracil phosphoribosyl transferase) genes which rendered HeLa cells sensitive to 5-FC and enhanced a bystander effect not mediated by gap junctions. However, 1% CD+–UPP+ cells were able to kill 40% of the cell population if the cells were communicating. This suggests that, at very low percentages of CD+–UPP+ cells, CodA and upp induce a bystander effect through gap junction-dependent mechanisms. 相似文献
100.